News | February 7, 2014

Bioline Launches High Performance SensiFAST cDNA Synthesis Kit

CINCINNATI--(BUSINESS WIRE)--

Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFASTTM cDNA synthesis kit. Powered by a newly developed Reverse Transcriptase enzyme with enhanced properties and in combination with the unique TransAmp™ buffer; SensiFASTTM cDNA synthesis kit is the choice for scientists who need consistent, unbiased, first-strand cDNA synthesis necessary for high sensitivity real-time PCR experiments.

The kit generates real-time ready first strand cDNA from viral RNA or total RNA and owes much of its high performance to the TransAmp™ buffer. This novel buffer includes a highly optimized blend of random and anchored oligo(dT) primers, to ensure RNA is accurately represented without bias in the generated cDNA. Furthermore, it is designed to overcome challenging secondary structures in a 42oC reaction, which is the optimal temperature for the new enzyme. Similar to SensiFAST™ real-time kits, the cDNA synthesis kit is both sensitive and fast, producing a valid representation of low copy RNA transcripts in a rapid 30 minute protocol.

Marco Calzavara, President of Bioline, commented, “The lack of bias and high cDNA yield leads to enhanced reproducibility and data accuracy over a wide dynamic range of RNA templates, making the SensiFAST™ cDNA synthesis kit the ideal partner for the popular range of high performance SensiFAST™ real-time PCR kits.”

Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are delighted to release the SensiFAST™ cDNA synthesis Kit, another addition to the rapidly expanding portfolio of reliable, highly specialized molecular biology reagents from Bioline. We are committed to our life science customers and to bringing innovation and quality products; such as the family of SensiFAST™ products to the research laboratory, clinical diagnostic laboratories, and biotechnology companies.”

ABOUT MERIDIAN BIOSCIENCE, INC.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

ADDITIONAL INFORMATION

For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard L. Eberly, rick.eberly@meridianbioscience.com


Copyright Business Wire 2014